<DOC>
	<DOC>NCT00838890</DOC>
	<brief_summary>To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer</brief_summary>
	<brief_title>A Study of BMS-863233 in Patients With Hematologic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>AML by current WHO diagnostic criteria, any FAB type (except APML), Refractory ALL, Accelerated/blast phase CML and Refractory MDS with total IPSS score of 2 or higher ECOG performance status &lt;= 2 Accessible for treatment, PK sample collection and required study followup Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 3 x ULN Women who are pregnant or breastfeeding Subjects with Acute Promyelocytic leukemia disease or CNS leukemia disease) Hyperleukocytosis (defined as peripheral WBC &gt;50,000/uL) Treatment with any other investigational agent for any indication within 30 days of protocol enrollment Subjects a history of gastrointestinal disease Subjects less than four weeks from allogenic or autologous stem cell transplant infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>